<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">akusherstvo</journal-id><journal-title-group><journal-title xml:lang="en">Obstetrics, Gynecology and Reproduction</journal-title><trans-title-group xml:lang="ru"><trans-title>Акушерство, Гинекология и Репродукция</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2313-7347</issn><issn pub-type="epub">2500-3194</issn><publisher><publisher-name>IRBIS LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.17749/2313-7347/ob.gyn.rep.2026.766</article-id><article-id custom-type="elpub" pub-id-type="custom">akusherstvo-2857</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>REVIEW ARTICLE</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>НАУЧНЫЙ ОБЗОР</subject></subj-group></article-categories><title-group><article-title>The role of genetic and epigenetic factors in developing polycystic ovary syndrome</article-title><trans-title-group xml:lang="ru"><trans-title>Роль генетических и эпигенетических факторов в развитии синдрома поликистозных яичников</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0008-9385-0149</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Коваль</surname><given-names>Ю. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Koval</surname><given-names>Yu. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Коваль Юлия Евгеньевна </p><p>119048 Москва, ул. Трубецкая, д. 8, стр. 2</p></bio><bio xml:lang="en"><p>Yulia E. Koval</p><p>8 bldg. 2, Trubetskaya Str., Moscow 119048</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0004-7414-2471</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Капырина</surname><given-names>Т. Д.</given-names></name><name name-style="western" xml:lang="en"><surname>Kapyrina</surname><given-names>T. D.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Капырина Татьяна Дмитриевна </p><p>119048 Москва, ул. Трубецкая, д. 8, стр. 2</p></bio><bio xml:lang="en"><p>Tatyana D. Kapyrina, MD</p><p>8 bldg. 2, Trubetskaya Str., Moscow 119048</p></bio><email xlink:type="simple">kapyrina_t_d@staff.sechenov.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9945-3848</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Игнатко</surname><given-names>И. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Ignatko</surname><given-names>I. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Игнатко Ирина Владимировна, д.м.н., проф., член-корр. РАН </p><p>Scopus Author ID: 15118951800.</p><p>WoS ResearcherID: ABA-6794-2021.</p><p>119048 Москва, ул. Трубецкая, д. 8, стр. 2</p></bio><bio xml:lang="en"><p>Irina V. Ignatko, MD, Dr Sci Med, Prof., Corresponding Member of RAS.</p><p>Scopus Author ID: 15118951800.</p><p>WoS ResearcherID: ABA-6794-2021.</p><p>8 bldg. 2, Trubetskaya Str., Moscow 119048</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7114-4050</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бахтияров</surname><given-names>К. Р.</given-names></name><name name-style="western" xml:lang="en"><surname>Bakhtiyarov</surname><given-names>K. R.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Бахтияров Камиль Рафаэльевич, д.м.н., проф.</p><p>Scopus Author ID: 57208396965.</p><p>119048 Москва, ул. Трубецкая, д. 8, стр. 2</p></bio><bio xml:lang="en"><p>Kamil R. Bakhtiyarov, MD, Dr Sci Med, Prof.</p><p>Scopus Author ID: 57208396965.</p><p>8 bldg. 2, Trubetskaya Str., Moscow 119048</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7215-5066</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гильмутдинова</surname><given-names>И. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Gilmutdinova</surname><given-names>I. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Гильмутдинова Ильсина Ильсуровна </p><p>119048 Москва, ул. Трубецкая, д. 8, стр. 2</p></bio><bio xml:lang="en"><p>Ilsina I. Gilmutdinova, MD</p><p>8 bldg. 2, Trubetskaya Str., Moscow 119048</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6433-2483</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Виривская</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Virivskaya</surname><given-names>E. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Виривская Елена Владимировна, к.м.н. </p><p>302026 Орел, Комсомольская ул., д. 95</p></bio><bio xml:lang="en"><p>Elena V. Virivskaya, MD, PhD</p><p>95 Komsomolskaya Str., Orеl 302026</p></bio><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГАОУ ВО Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский Университет)</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Sechenov University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБОУ ВО «Орловский государственный университет имени И.С. Тургенева»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Turgenev Orеl State University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="epub"><day>23</day><month>06</month><year>2026</year></pub-date><volume>0</volume><issue>0</issue><issue-title>Online First</issue-title><elocation-id>2857</elocation-id><permissions><copyright-statement>Copyright &amp;#x00A9; Koval Y.E., Kapyrina T.D., Ignatko I.V., Bakhtiyarov K.R., Gilmutdinova I.I., Virivskaya E.V., 2020</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="ru">Коваль Ю.Е., Капырина Т.Д., Игнатко И.В., Бахтияров К.Р., Гильмутдинова И.И., Виривская Е.В.</copyright-holder><copyright-holder xml:lang="en">Koval Y.E., Kapyrina T.D., Ignatko I.V., Bakhtiyarov K.R., Gilmutdinova I.I., Virivskaya E.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.gynecology.su/jour/article/view/2857">https://www.gynecology.su/jour/article/view/2857</self-uri><abstract><p>Polycystic ovary syndrome (PCOS) is one of the most common endocrine and metabolic disorders in women of reproductive age, affecting health throughout the lifespan. The etiology of this condition includes genetic factors such as polymorphisms of the CYP11A1, CYP17A1, and DENND1A genes-related epigenetic mechanisms (including promoter methylation of genes associated with steroid hormone synthesis and insulin signaling, as well as the role of microRNAs in regulating folliculogenesis and hyperandrogenism), and environmental cues (diet, stress, and exogenous toxins). Together, these mechanisms lead to dysregulated steroidogenesis, hyperandrogenism, anovulation, and insulin resistance, resulting in heterogeneous clinical phenotypes. The aim of this review is to comprehensively analyze current evidence on the role played by genetic and epigenetic factors in PCOS development and to explore potential application of such findings for improving early diagnosis and developing novel therapeutic approaches.</p></abstract><trans-abstract xml:lang="ru"><p>Синдром поликистозных яичников (СПКЯ) является одним из наиболее распространенных эндокринных и метаболических расстройств у женщин репродуктивного возраста, оказывающее влияние на здоровье в течение всей жизни. Среди причин развития данной патологии выделяют генетические факторы – полиморфизмы генов CYP11A1, CYP17A1, DENND1A, эпигенетические (метилирование промоторов генов, ассоциированных с синтезом стероидных гормонов и инсулиновой сигнализацией, роль микроРНК в регуляции фолликулогенеза и гиперандрогении), а также факторы окружающей среды (диета, стресс, экзогенные токсины). Совместно эти механизмы приводят к дисфункции стероидогенеза, гиперандрогении, ановуляции, инсулинорезистентности, формируя гетерогенные клинические фенотипы. Проведен комплексный анализ современных данных о роли генетических и эпигенетических факторов в развитии СПКЯ для рассмотрения перспектив применения полученных данных для совершенствования ранней диагностики и разработки новых схем лечения.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>синдром поликистозных яичников СПКЯ</kwd><kwd>генетика</kwd><kwd>эпигенетика</kwd><kwd>метилирование ДНК</kwd><kwd>микроРНК</kwd><kwd>гиперандрогения</kwd><kwd>инсулинорезистентность</kwd><kwd>ожирение</kwd></kwd-group><kwd-group xml:lang="en"><kwd>polycystic ovary syndrome</kwd><kwd>PCOS</kwd><kwd>genetics</kwd><kwd>epigenetics</kwd><kwd>DNA methylation</kwd><kwd>microRNA</kwd><kwd>hyperandrogenism</kwd><kwd>insulin resistance</kwd><kwd>obesity</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Teede H.J., Tay C.T., Laven J. et al. Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. J Clin Endocrinol Metab. 2023;108(10):2447–69. https://doi.org/10.1093/ejendo/lvad096.</mixed-citation><mixed-citation xml:lang="en">Teede H.J., Tay C.T., Laven J. et al. Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. J Clin Endocrinol Metab. 2023;108(10):2447–69. https://doi.org/10.1093/ejendo/lvad096.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Stener-Victorin E., Deng Q. Epigenetic inheritance of polycystic ovary syndrome: challenges and opportunities for treatment. Nat Rev Endocrinol. 2021;17(9):521–33. https://doi.org/10.1038/s41574-021-00517-x.</mixed-citation><mixed-citation xml:lang="en">Stener-Victorin E., Deng Q. Epigenetic inheritance of polycystic ovary syndrome: challenges and opportunities for treatment. Nat Rev Endocrinol. 2021;17(9):521–33. https://doi.org/10.1038/s41574-021-00517-x.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Hum Reprod. 2004;19(1):41–7. https://doi.org/10.1093/humrep/deh098.</mixed-citation><mixed-citation xml:lang="en">Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Hum Reprod. 2004;19(1):41–7. https://doi.org/10.1093/humrep/deh098.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Mills G., Badeghiesh A., Suarthana E. et al. Polycystic ovary syndrome as an independent risk factor for gestational diabetes and hypertensive disorders of pregnancy: a population-based study on 9.1 million pregnancies. Hum Reprod. 2020;35(7):1666–74. https://doi.org/10.1093/humrep/deaa099.</mixed-citation><mixed-citation xml:lang="en">Mills G., Badeghiesh A., Suarthana E. et al. Polycystic ovary syndrome as an independent risk factor for gestational diabetes and hypertensive disorders of pregnancy: a population-based study on 9.1 million pregnancies. Hum Reprod. 2020;35(7):1666–74. https://doi.org/10.1093/humrep/deaa099.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Pan H., Xian P., Yang D. et al. Polycystic ovary syndrome as an independent risk factor for hypertensive disorders of pregnancy: a systematic review, meta-analysis, and meta-regression. Endocrine. 2021;74(3):518–29. https://doi.org/10.1007/s12020-021-02886-9.</mixed-citation><mixed-citation xml:lang="en">Pan H., Xian P., Yang D. et al. Polycystic ovary syndrome as an independent risk factor for hypertensive disorders of pregnancy: a systematic review, meta-analysis, and meta-regression. Endocrine. 2021;74(3):518–29. https://doi.org/10.1007/s12020-021-02886-9.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Wang Y., Xiang T., Xia X. et al. Elevated circulating GPHB5 levels in women with insulin resistance and polycystic ovary syndrome: a cross-sectional study and multiple intervention studies. Front Endocrinol (Lausanne). 2022;13:1010714. https://doi.org/10.3389/fendo.2022.1010714.</mixed-citation><mixed-citation xml:lang="en">Wang Y., Xiang T., Xia X. et al. Elevated circulating GPHB5 levels in women with insulin resistance and polycystic ovary syndrome: a cross-sectional study and multiple intervention studies. Front Endocrinol (Lausanne). 2022;13:1010714. https://doi.org/10.3389/fendo.2022.1010714.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Forslund M., Schmidt J., Brännström M. Morbidity and mortality in PCOS: a prospective follow-up up to a mean age above 80 years. Eur J Obstet Gynecol Reprod Biol. 2022;271:195–203. https://doi.org/10.1016/j.ejogrb.2022.02.020/</mixed-citation><mixed-citation xml:lang="en">Forslund M., Schmidt J., Brännström M. Morbidity and mortality in PCOS: a prospective follow-up up to a mean age above 80 years. Eur J Obstet Gynecol Reprod Biol. 2022;271:195–203. https://doi.org/10.1016/j.ejogrb.2022.02.020/</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Yadav S., Delau O., Bonner A.J. et al. Direct economic burden of mental health disorders associated with polycystic ovary syndrome: systematic review and meta-analysis. eLife. 2023;12:e85338. https://doi.org/10.7554/eLife.85338.</mixed-citation><mixed-citation xml:lang="en">Yadav S., Delau O., Bonner A.J. et al. Direct economic burden of mental health disorders associated with polycystic ovary syndrome: systematic review and meta-analysis. eLife. 2023;12:e85338. https://doi.org/10.7554/eLife.85338.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Yuan H., Zhu G., Wang F.et al. Interaction between common variants of FTO and MC4R is associated with risk of PCOS. Reprod Biol Endocrinol. 2015;13:55. https://doi.org/10.1186/s12958-015-0050-z.</mixed-citation><mixed-citation xml:lang="en">Yuan H., Zhu G., Wang F.et al. Interaction between common variants of FTO and MC4R is associated with risk of PCOS. Reprod Biol Endocrinol. 2015;13:55. https://doi.org/10.1186/s12958-015-0050-z.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Zeng X., Xie Y.J., Liu Y.T. et al. Polycystic ovarian syndrome: correlation between hyperandrogenism, insulin resistance and obesity. Clin Chim Acta. 2020;502:214–21. https://doi.org/10.1016/j.cca.2019.11.003.</mixed-citation><mixed-citation xml:lang="en">Zeng X., Xie Y.J., Liu Y.T. et al. Polycystic ovarian syndrome: correlation between hyperandrogenism, insulin resistance and obesity. Clin Chim Acta. 2020;502:214–21. https://doi.org/10.1016/j.cca.2019.11.003.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Hall J.E., Taylor A.E., Hayes F.J., Crowley W.F. Insights into hypothalamic-pituitary dysfunction in polycystic ovary syndrome. J Endocrinol Invest. 1998;21(9):602–11. https://doi.org/10.1007/BF03350785.</mixed-citation><mixed-citation xml:lang="en">Hall J.E., Taylor A.E., Hayes F.J., Crowley W.F. Insights into hypothalamic-pituitary dysfunction in polycystic ovary syndrome. J Endocrinol Invest. 1998;21(9):602–11. https://doi.org/10.1007/BF03350785.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Ajmal N., Khan S.Z., Shaikh R. Polycystic ovary syndrome and genetic predisposition: a review. Eur J Obstet Gynecol Reprod Biol X. 2019;3:100060. https://doi.org/10.1016/j.eurox.2019.100060.</mixed-citation><mixed-citation xml:lang="en">Ajmal N., Khan S.Z., Shaikh R. Polycystic ovary syndrome and genetic predisposition: a review. Eur J Obstet Gynecol Reprod Biol X. 2019;3:100060. https://doi.org/10.1016/j.eurox.2019.100060.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Garg A., Patel B., Abbara A., Dhillo W.S. Treatments targeting neuroendocrine dysfunction in polycystic ovary syndrome. Clin Endocrinol (Oxf). 2022;97(2):156–64. https://doi.org/10.1111/cen.14704.</mixed-citation><mixed-citation xml:lang="en">Garg A., Patel B., Abbara A., Dhillo W.S. Treatments targeting neuroendocrine dysfunction in polycystic ovary syndrome. Clin Endocrinol (Oxf). 2022;97(2):156–64. https://doi.org/10.1111/cen.14704.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Dong J., Rees D.A. Polycystic ovary syndrome: pathophysiology and therapeutic opportunities. BMJ Med. 2023;2:e000548. https://doi.org/10.1136/bmjmed-2023-000548.</mixed-citation><mixed-citation xml:lang="en">Dong J., Rees D.A. Polycystic ovary syndrome: pathophysiology and therapeutic opportunities. BMJ Med. 2023;2:e000548. https://doi.org/10.1136/bmjmed-2023-000548.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Yang J., Chen C. Hormonal changes in PCOS. J Endocrinol. 2024;261(1):e230342. https://doi.org/10.1530/JOE-23-0342.</mixed-citation><mixed-citation xml:lang="en">Yang J., Chen C. Hormonal changes in PCOS. J Endocrinol. 2024;261(1):e230342. https://doi.org/10.1530/JOE-23-0342.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Xia Q., Xie L., Wu Q. et al. Elevated baseline LH/FSH ratio is associated with poor ovulatory response but better clinical pregnancy and live birth in Chinese women with PCOS after ovulation induction. Heliyon. 2023;9(1):e13024. https://doi.org/10.1016/j.heliyon.2023.e13024.</mixed-citation><mixed-citation xml:lang="en">Xia Q., Xie L., Wu Q. et al. Elevated baseline LH/FSH ratio is associated with poor ovulatory response but better clinical pregnancy and live birth in Chinese women with PCOS after ovulation induction. Heliyon. 2023;9(1):e13024. https://doi.org/10.1016/j.heliyon.2023.e13024.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Hu K.L., Chen Z., Li X. et al. Advances in clinical applications of kisspeptin-GnRH pathway in female reproduction. Reprod Biol Endocrinol. 2022;20(1):81. https://doi.org/10.1186/s12958-022-00953-y.</mixed-citation><mixed-citation xml:lang="en">Hu K.L., Chen Z., Li X. et al. Advances in clinical applications of kisspeptin-GnRH pathway in female reproduction. Reprod Biol Endocrinol. 2022;20(1):81. https://doi.org/10.1186/s12958-022-00953-y.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Katulski K., Podfigurna A., Czyzyk A. et al. Kisspeptin and LH pulsatile temporal coupling in PCOS patients. Endocrine. 2018;61(1):149–57. https://doi.org/10.1007/s12020-018-1609-1.</mixed-citation><mixed-citation xml:lang="en">Katulski K., Podfigurna A., Czyzyk A. et al. Kisspeptin and LH pulsatile temporal coupling in PCOS patients. Endocrine. 2018;61(1):149–57. https://doi.org/10.1007/s12020-018-1609-1.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Ruka K.A., Burger L.L., Moenter S.M. Regulation of arcuate neurons coexpressing kisspeptin, neurokinin B, and dynorphin by modulators of neurokinin 3 and κ-opioid receptors in adult male mice. Endocrinology. 2013;154(8):2761–71. https://doi.org/10.1210/en.2013-1268.</mixed-citation><mixed-citation xml:lang="en">Ruka K.A., Burger L.L., Moenter S.M. Regulation of arcuate neurons coexpressing kisspeptin, neurokinin B, and dynorphin by modulators of neurokinin 3 and κ-opioid receptors in adult male mice. Endocrinology. 2013;154(8):2761–71. https://doi.org/10.1210/en.2013-1268.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Ruddenklau A., Campbell R.E. Neuroendocrine impairments of polycystic ovary syndrome. Endocrinology. 2019;160(10):2230–42. https://doi.org/10.1210/en.2019-00428/</mixed-citation><mixed-citation xml:lang="en">Ruddenklau A., Campbell R.E. Neuroendocrine impairments of polycystic ovary syndrome. Endocrinology. 2019;160(10):2230–42. https://doi.org/10.1210/en.2019-00428/</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Yang J.J., Caligioni C.S., Chan Y.M., Seminara S.B. Uncovering novel reproductive defects in neurokinin B receptor null mice: closing the gap between mice and men. Endocrinology. 2012;153(3):1498–508. https://doi.org/10.1210/en.2011-1949.</mixed-citation><mixed-citation xml:lang="en">Yang J.J., Caligioni C.S., Chan Y.M., Seminara S.B. Uncovering novel reproductive defects in neurokinin B receptor null mice: closing the gap between mice and men. Endocrinology. 2012;153(3):1498–508. https://doi.org/10.1210/en.2011-1949.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Clarkson J., Han S.Y., Piet R. et al. Definition of the hypothalamic GnRH pulse generator in mice. Proc Natl Acad Sci U S A. 2017;114(47):E10216-E10223. https://doi.org/10.1073/pnas.1713897114.</mixed-citation><mixed-citation xml:lang="en">Clarkson J., Han S.Y., Piet R. et al. Definition of the hypothalamic GnRH pulse generator in mice. Proc Natl Acad Sci U S A. 2017;114(47):E10216-E10223. https://doi.org/10.1073/pnas.1713897114.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Goodman R.L., Coolen L.M., Anderson G.M., Hardy S.L., Valent M., Connors J.M., et al. Evidence that dynorphin plays a major role in mediating progesterone negative feedback on gonadotropin-releasing hormone neurons in sheep. Endocrinology. 2004;145(6):2959–67. https://doi.org/10.1210/en.2003-1305.</mixed-citation><mixed-citation xml:lang="en">Goodman R.L., Coolen L.M., Anderson G.M., Hardy S.L., Valent M., Connors J.M., et al. Evidence that dynorphin plays a major role in mediating progesterone negative feedback on gonadotropin-releasing hormone neurons in sheep. Endocrinology. 2004;145(6):2959–67. https://doi.org/10.1210/en.2003-1305.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Keen K.L., Petersen A.J., Figueroa A.G. et al. Physiological characterization and transcriptomic properties of GnRH neurons derived from human stem cells. Endocrinology. 2021;162(9):bqab120. https://doi.org/10.1210/endocr/bqab120.</mixed-citation><mixed-citation xml:lang="en">Keen K.L., Petersen A.J., Figueroa A.G. et al. Physiological characterization and transcriptomic properties of GnRH neurons derived from human stem cells. Endocrinology. 2021;162(9):bqab120. https://doi.org/10.1210/endocr/bqab120.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Yazawa T., Watanabe Y., Yokohama Y. et al. Evaluation of 3β-hydroxysteroid dehydrogenase activity using progesterone- and androgen receptor–mediated transactivation. Front Endocrinol (Lausanne). 2024;15:1480722. https://doi.org/10.3389/fendo.2024.1480722.</mixed-citation><mixed-citation xml:lang="en">Yazawa T., Watanabe Y., Yokohama Y. et al. Evaluation of 3β-hydroxysteroid dehydrogenase activity using progesterone- and androgen receptor–mediated transactivation. Front Endocrinol (Lausanne). 2024;15:1480722. https://doi.org/10.3389/fendo.2024.1480722.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Penning T.M., Wangtrakuldee P., Auchus R.J. Structural and functional biology of aldo-keto reductase steroid-transforming enzymes. Endocr Rev. 2019;40(2):447–75. https://doi.org/10.1210/er.2018-00089.</mixed-citation><mixed-citation xml:lang="en">Penning T.M., Wangtrakuldee P., Auchus R.J. Structural and functional biology of aldo-keto reductase steroid-transforming enzymes. Endocr Rev. 2019;40(2):447–75. https://doi.org/10.1210/er.2018-00089.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Loerz C., Maser E. The cortisol-activating enzyme 11β-hydroxysteroid dehydrogenase type 1 in skeletal muscle in the pathogenesis of the metabolic syndrome. J Steroid Biochem Mol Biol. 2017;174:65–71. https://doi.org/10.1016/j.jsbmb.2017.07.030.</mixed-citation><mixed-citation xml:lang="en">Loerz C., Maser E. The cortisol-activating enzyme 11β-hydroxysteroid dehydrogenase type 1 in skeletal muscle in the pathogenesis of the metabolic syndrome. J Steroid Biochem Mol Biol. 2017;174:65–71. https://doi.org/10.1016/j.jsbmb.2017.07.030.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Li X., Hu S., Zhu Q. et al. Addressing the role of 11β-hydroxysteroid dehydrogenase type 1 in the development of polycystic ovary syndrome and the putative therapeutic effects of its selective inhibition in a preclinical model. Metabolism. 2021;119:154749. https://doi.org/10.1016/j.metabol.2021.154749.</mixed-citation><mixed-citation xml:lang="en">Li X., Hu S., Zhu Q. et al. Addressing the role of 11β-hydroxysteroid dehydrogenase type 1 in the development of polycystic ovary syndrome and the putative therapeutic effects of its selective inhibition in a preclinical model. Metabolism. 2021;119:154749. https://doi.org/10.1016/j.metabol.2021.154749.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Gambineri A., Fanelli F., Tomassoni F. et al. Tissue-specific dysregulation of 11β-hydroxysteroid dehydrogenase type 1 in overweight/obese women with polycystic ovary syndrome compared with weight-matched controls. Eur J Endocrinol. 2014;171(1):47–57. https://doi.org/10.1530/EJE-13-1030.</mixed-citation><mixed-citation xml:lang="en">Gambineri A., Fanelli F., Tomassoni F. et al. Tissue-specific dysregulation of 11β-hydroxysteroid dehydrogenase type 1 in overweight/obese women with polycystic ovary syndrome compared with weight-matched controls. Eur J Endocrinol. 2014;171(1):47–57. https://doi.org/10.1530/EJE-13-1030.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Yildiz B.O., Azziz R. The adrenal and polycystic ovary syndrome. Rev Endocr Metab Disord. 2007;8(4):331–42. https://doi.org/10.1007/s11154-007-9054-0.</mixed-citation><mixed-citation xml:lang="en">Yildiz B.O., Azziz R. The adrenal and polycystic ovary syndrome. Rev Endocr Metab Disord. 2007;8(4):331–42. https://doi.org/10.1007/s11154-007-9054-0.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Guengerich F.P., McCarty K.D., Tateishi Y., Liu L. Steroid 17α-hydroxylase/17,20-lyase (cytochrome P450 17A1). Methods Enzymol. 2023;689:39–63. https://doi.org/10.1016/bs.mie.2023.04.001.</mixed-citation><mixed-citation xml:lang="en">Guengerich F.P., McCarty K.D., Tateishi Y., Liu L. Steroid 17α-hydroxylase/17,20-lyase (cytochrome P450 17A1). Methods Enzymol. 2023;689:39–63. https://doi.org/10.1016/bs.mie.2023.04.001.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Paulukinas R.D., Mesaros C.A., Penning T.M. Conversion of classical and 11-oxygenated androgens by insulin-induced AKR1C3 in a model of human PCOS adipocytes. Endocrinology. 2022;163(7):bqac068. https://doi.org/10.1210/endocr/bqac068.</mixed-citation><mixed-citation xml:lang="en">Paulukinas R.D., Mesaros C.A., Penning T.M. Conversion of classical and 11-oxygenated androgens by insulin-induced AKR1C3 in a model of human PCOS adipocytes. Endocrinology. 2022;163(7):bqac068. https://doi.org/10.1210/endocr/bqac068.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">O’Reilly M.W., Kempegowda P., Jenkinson C. et al. 11-Oxygenated C19 steroids are the predominant androgens in polycystic ovary syndrome. J Clin Endocrinol Metab. 2017;102(3):840–8. https://doi.org/10.1210/jc.2016-3285.</mixed-citation><mixed-citation xml:lang="en">O’Reilly M.W., Kempegowda P., Jenkinson C. et al. 11-Oxygenated C19 steroids are the predominant androgens in polycystic ovary syndrome. J Clin Endocrinol Metab. 2017;102(3):840–8. https://doi.org/10.1210/jc.2016-3285.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">O’Reilly M.W., Kempegowda P., Walsh M. et al. AKR1C3-mediated adipose androgen generation drives lipotoxicity in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2017;102(9):3327–39. https://doi.org/10.1210/jc.2017-00947.</mixed-citation><mixed-citation xml:lang="en">O’Reilly M.W., Kempegowda P., Walsh M. et al. AKR1C3-mediated adipose androgen generation drives lipotoxicity in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2017;102(9):3327–39. https://doi.org/10.1210/jc.2017-00947.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Turcu A.F., Rege J., Auchus R.J., Rainey W.E. 11-Oxygenated androgens in health and disease. Nat Rev Endocrinol. 2020;16(5):284–96. https://doi.org/10.1038/s41574-020-0336-x.</mixed-citation><mixed-citation xml:lang="en">Turcu A.F., Rege J., Auchus R.J., Rainey W.E. 11-Oxygenated androgens in health and disease. Nat Rev Endocrinol. 2020;16(5):284–96. https://doi.org/10.1038/s41574-020-0336-x.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Bansal B., Thazhuthadath Kishore A., Kathiresan S. et al. A systematic review of inflammatory markers in polycystic ovary syndrome and meta-analysis of interleukin-6 in case-control studies. Cureus. 2025;17(4):e82350. https://doi.org/10.7759/cureus.82350.</mixed-citation><mixed-citation xml:lang="en">Bansal B., Thazhuthadath Kishore A., Kathiresan S. et al. A systematic review of inflammatory markers in polycystic ovary syndrome and meta-analysis of interleukin-6 in case-control studies. Cureus. 2025;17(4):e82350. https://doi.org/10.7759/cureus.82350.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Wang K., Li Y., Chen Y. Androgen excess: a hallmark of polycystic ovary syndrome. Front Endocrinol (Lausanne). 2023;14:1273542. https://doi.org/10.3389/fendo.2023.1273542.</mixed-citation><mixed-citation xml:lang="en">Wang K., Li Y., Chen Y. Androgen excess: a hallmark of polycystic ovary syndrome. Front Endocrinol (Lausanne). 2023;14:1273542. https://doi.org/10.3389/fendo.2023.1273542.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Joham A.E., Teede H.J. PCOS – a metabolic condition with health impacts on women and men. Nat Rev Endocrinol. 2022;18(4):197–8. https://doi.org/10.1038/s41574-022-00636-z.</mixed-citation><mixed-citation xml:lang="en">Joham A.E., Teede H.J. PCOS – a metabolic condition with health impacts on women and men. Nat Rev Endocrinol. 2022;18(4):197–8. https://doi.org/10.1038/s41574-022-00636-z.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Puttabyatappa M., Sargis R.M., Padmanabhan V. Developmental programming of insulin resistance: are androgens the culprits? J Endocrinol. 2020;245(3):R23–R48. https://doi.org/10.1530/JOE-20-0044.</mixed-citation><mixed-citation xml:lang="en">Puttabyatappa M., Sargis R.M., Padmanabhan V. Developmental programming of insulin resistance: are androgens the culprits? J Endocrinol. 2020;245(3):R23–R48. https://doi.org/10.1530/JOE-20-0044.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Stepto N.K., Moreno-Asso A., McIlvenna L.C. et al. Molecular mechanisms of insulin resistance in polycystic ovary syndrome: unraveling the conundrum in skeletal muscle? J Clin Endocrinol Metab. 2019;104(11):5372–81. https://doi.org/10.1210/jc.2019-00167.</mixed-citation><mixed-citation xml:lang="en">Stepto N.K., Moreno-Asso A., McIlvenna L.C. et al. Molecular mechanisms of insulin resistance in polycystic ovary syndrome: unraveling the conundrum in skeletal muscle? J Clin Endocrinol Metab. 2019;104(11):5372–81. https://doi.org/10.1210/jc.2019-00167.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Joham A.E., Norman R.J., Stener-Victorin E. et al. Polycystic ovary syndrome. Lancet Diabetes Endocrinol. 2022;10(9):668–80. https://doi.org/10.1016/S2213-8587(22)00163-2.</mixed-citation><mixed-citation xml:lang="en">Joham A.E., Norman R.J., Stener-Victorin E. et al. Polycystic ovary syndrome. Lancet Diabetes Endocrinol. 2022;10(9):668–80. https://doi.org/10.1016/S2213-8587(22)00163-2.</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Fernandez-Twinn D.S., Alfaradhi M.Z., Martin-Gronert M.S. et al. Downregulation of IRS-1 in adipose tissue of offspring of obese mice is programmed cell-autonomously through post-transcriptional mechanisms. Mol Metab. 2014;3(3):325–33. https://doi.org/10.1016/j.molmet.2014.01.007.</mixed-citation><mixed-citation xml:lang="en">Fernandez-Twinn D.S., Alfaradhi M.Z., Martin-Gronert M.S. et al. Downregulation of IRS-1 in adipose tissue of offspring of obese mice is programmed cell-autonomously through post-transcriptional mechanisms. Mol Metab. 2014;3(3):325–33. https://doi.org/10.1016/j.molmet.2014.01.007.</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Rudnicka E., Suchta K., Grymowicz M. et al. Chronic low-grade inflammation in the pathogenesis of polycystic ovary syndrome. Int J Mol Sci. 2021;22(7):3789. https://doi.org/10.3390/ijms22073789.</mixed-citation><mixed-citation xml:lang="en">Rudnicka E., Suchta K., Grymowicz M. et al. Chronic low-grade inflammation in the pathogenesis of polycystic ovary syndrome. Int J Mol Sci. 2021;22(7):3789. https://doi.org/10.3390/ijms22073789.</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Amisi C.A. Markers of insulin resistance in women with polycystic ovary syndrome: an update. World J Diabetes. 2022;13(3):129–49. https://doi.org/10.4239/wjd.v13.i3.129.</mixed-citation><mixed-citation xml:lang="en">Amisi C.A. Markers of insulin resistance in women with polycystic ovary syndrome: an update. World J Diabetes. 2022;13(3):129–49. https://doi.org/10.4239/wjd.v13.i3.129.</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Rosenfield R.L., Ehrmann D.A. The pathogenesis of polycystic ovary syndrome: the hypothesis of PCOS as functional ovarian hyperandrogenism revisited. Endocr Rev. 2016;37(5):467–520. https://doi.org/10.1210/er.2015-1104.</mixed-citation><mixed-citation xml:lang="en">Rosenfield R.L., Ehrmann D.A. The pathogenesis of polycystic ovary syndrome: the hypothesis of PCOS as functional ovarian hyperandrogenism revisited. Endocr Rev. 2016;37(5):467–520. https://doi.org/10.1210/er.2015-1104.</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Cassar S., Misso M.L., Hopkins W.G. et al. Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemic-hyperinsulinaemic clamp studies. Hum Reprod. 2016;31(11):2619–31. https://doi.org/10.1093/humrep/dew243.</mixed-citation><mixed-citation xml:lang="en">Cassar S., Misso M.L., Hopkins W.G. et al. Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemic-hyperinsulinaemic clamp studies. Hum Reprod. 2016;31(11):2619–31. https://doi.org/10.1093/humrep/dew243.</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Stener-Victorin E., Deng Q. Epigenetic inheritance of PCOS by developmental programming and germline transmission. Trends Endocrinol Metab. 2025;36(5):472–81. https://doi.org/10.1016/j.tem.2024.12.002.</mixed-citation><mixed-citation xml:lang="en">Stener-Victorin E., Deng Q. Epigenetic inheritance of PCOS by developmental programming and germline transmission. Trends Endocrinol Metab. 2025;36(5):472–81. https://doi.org/10.1016/j.tem.2024.12.002.</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Tan H., Long P., Xiao H. Dissecting the shared genetic architecture between endometriosis and polycystic ovary syndrome. Front Endocrinol (Lausanne). 2024;15:1359236. https://doi.org/10.3389/fendo.2024.1359236.</mixed-citation><mixed-citation xml:lang="en">Tan H., Long P., Xiao H. Dissecting the shared genetic architecture between endometriosis and polycystic ovary syndrome. Front Endocrinol (Lausanne). 2024;15:1359236. https://doi.org/10.3389/fendo.2024.1359236.</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Gorsic L.K., Dapas M., Legro R.S. et al. Functional genetic variation in the anti-Müllerian hormone pathway in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2019;104(7):2855–74. https://doi.org/10.1210/jc.2018-02178.</mixed-citation><mixed-citation xml:lang="en">Gorsic L.K., Dapas M., Legro R.S. et al. Functional genetic variation in the anti-Müllerian hormone pathway in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2019;104(7):2855–74. https://doi.org/10.1210/jc.2018-02178.</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Dapas M., Sisk R., Legro R.S. et al. Family-based quantitative trait meta-analysis implicates rare noncoding variants in DENND1A in polycystic ovary syndrome. J Clin Endocrinol Metab. 2019;104(9):3835–50. https://doi.org/10.1210/jc.2018-02496.</mixed-citation><mixed-citation xml:lang="en">Dapas M., Sisk R., Legro R.S. et al. Family-based quantitative trait meta-analysis implicates rare noncoding variants in DENND1A in polycystic ovary syndrome. J Clin Endocrinol Metab. 2019;104(9):3835–50. https://doi.org/10.1210/jc.2018-02496.</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">Sun S., Liu Y., Li L. et al. Unveiling the shared genetic architecture between testosterone and polycystic ovary syndrome. Sci Rep. 2024;14(1):23931. https://doi.org/10.1038/s41598-024-75816-0.</mixed-citation><mixed-citation xml:lang="en">Sun S., Liu Y., Li L. et al. Unveiling the shared genetic architecture between testosterone and polycystic ovary syndrome. Sci Rep. 2024;14(1):23931. https://doi.org/10.1038/s41598-024-75816-0.</mixed-citation></citation-alternatives></ref><ref id="cit52"><label>52</label><citation-alternatives><mixed-citation xml:lang="ru">McAllister J.M., Modi B., Miller B.A. et al. Overexpression of a DENND1A isoform produces a polycystic ovary syndrome theca phenotype. Proc Natl Acad Sci U S A. 2014;111(15):E1519–E1527. https://doi.org/10.1073/pnas.1400574111.</mixed-citation><mixed-citation xml:lang="en">McAllister J.M., Modi B., Miller B.A. et al. Overexpression of a DENND1A isoform produces a polycystic ovary syndrome theca phenotype. Proc Natl Acad Sci U S A. 2014;111(15):E1519–E1527. https://doi.org/10.1073/pnas.1400574111.</mixed-citation></citation-alternatives></ref><ref id="cit53"><label>53</label><citation-alternatives><mixed-citation xml:lang="ru">Porter D.T., Moore A.M., Cobern J.A. et al. Prenatal testosterone exposure alters GABAergic synaptic inputs to GnRH and KNDy neurons in a sheep model of polycystic ovarian syndrome. Endocrinology. 2019;160(11):2529–42. https://doi.org/10.1210/en.2019-00137.</mixed-citation><mixed-citation xml:lang="en">Porter D.T., Moore A.M., Cobern J.A. et al. Prenatal testosterone exposure alters GABAergic synaptic inputs to GnRH and KNDy neurons in a sheep model of polycystic ovarian syndrome. Endocrinology. 2019;160(11):2529–42. https://doi.org/10.1210/en.2019-00137.</mixed-citation></citation-alternatives></ref><ref id="cit54"><label>54</label><citation-alternatives><mixed-citation xml:lang="ru">Albalawi F.S., Daghestani M.H., Eldali A., Warsy A.S. rs4889 polymorphism in KISS1 gene, its effect on polycystic ovary syndrome development and anthropometric and hormonal parameters in Saudi women. J Biomed Sci. 2018;25(1):50. https://doi.org/10.1186/s12929-018-0452-2.</mixed-citation><mixed-citation xml:lang="en">Albalawi F.S., Daghestani M.H., Eldali A., Warsy A.S. rs4889 polymorphism in KISS1 gene, its effect on polycystic ovary syndrome development and anthropometric and hormonal parameters in Saudi women. J Biomed Sci. 2018;25(1):50. https://doi.org/10.1186/s12929-018-0452-2.</mixed-citation></citation-alternatives></ref><ref id="cit55"><label>55</label><citation-alternatives><mixed-citation xml:lang="ru">Daghestani M.H., Daghistani M., Ambreen K. et al. Influence of KISS1 gene polymorphisms on the risk of polycystic ovary syndrome and its associated variables in Saudi women. BMC Endocr Disord. 2020;20(1):59. https://doi.org/10.1186/s12902-020-0537-2.</mixed-citation><mixed-citation xml:lang="en">Daghestani M.H., Daghistani M., Ambreen K. et al. Influence of KISS1 gene polymorphisms on the risk of polycystic ovary syndrome and its associated variables in Saudi women. BMC Endocr Disord. 2020;20(1):59. https://doi.org/10.1186/s12902-020-0537-2.</mixed-citation></citation-alternatives></ref><ref id="cit56"><label>56</label><citation-alternatives><mixed-citation xml:lang="ru">Liang J., Lan J., Li M., Wang F. Associations of leptin receptor and peroxisome proliferator-activated receptor gamma polymorphisms with polycystic ovary syndrome: a meta-analysis. Ann Nutr Metab. 2019;75(1):1–8. https://doi.org/10.1159/000500996.</mixed-citation><mixed-citation xml:lang="en">Liang J., Lan J., Li M., Wang F. Associations of leptin receptor and peroxisome proliferator-activated receptor gamma polymorphisms with polycystic ovary syndrome: a meta-analysis. Ann Nutr Metab. 2019;75(1):1–8. https://doi.org/10.1159/000500996.</mixed-citation></citation-alternatives></ref><ref id="cit57"><label>57</label><citation-alternatives><mixed-citation xml:lang="ru">Dallel M., Douma Z., Finan R.R. et al. Contrasting association of leptin receptor polymorphisms and haplotypes with polycystic ovary syndrome in Bahraini and Tunisian women: a case-control study. Biosci Rep. 2021;41(1):BSR20202726. https://doi.org/10.1042/BSR20202726.</mixed-citation><mixed-citation xml:lang="en">Dallel M., Douma Z., Finan R.R. et al. Contrasting association of leptin receptor polymorphisms and haplotypes with polycystic ovary syndrome in Bahraini and Tunisian women: a case-control study. Biosci Rep. 2021;41(1):BSR20202726. https://doi.org/10.1042/BSR20202726.</mixed-citation></citation-alternatives></ref><ref id="cit58"><label>58</label><citation-alternatives><mixed-citation xml:lang="ru">Pereira S., Cline D.L., Glavas M.M. et al. Tissue-specific effects of leptin on glucose and lipid metabolism. Endocr Rev. 2021;42(1):1–28. https://doi.org/10.1210/endrev/bnaa027.</mixed-citation><mixed-citation xml:lang="en">Pereira S., Cline D.L., Glavas M.M. et al. Tissue-specific effects of leptin on glucose and lipid metabolism. Endocr Rev. 2021;42(1):1–28. https://doi.org/10.1210/endrev/bnaa027.</mixed-citation></citation-alternatives></ref><ref id="cit59"><label>59</label><citation-alternatives><mixed-citation xml:lang="ru">Heidarzadehpilehrood R., Pirhoushiaran M., Abdollahzadeh R. et al. A review on CYP11A1, CYP17A1, and CYP19A1 polymorphism studies: candidate susceptibility genes for polycystic ovary syndrome and infertility. Genes (Basel). 2022;13(2):302. https://doi.org/10.3390/genes13020302.</mixed-citation><mixed-citation xml:lang="en">Heidarzadehpilehrood R., Pirhoushiaran M., Abdollahzadeh R. et al. A review on CYP11A1, CYP17A1, and CYP19A1 polymorphism studies: candidate susceptibility genes for polycystic ovary syndrome and infertility. Genes (Basel). 2022;13(2):302. https://doi.org/10.3390/genes13020302.</mixed-citation></citation-alternatives></ref><ref id="cit60"><label>60</label><citation-alternatives><mixed-citation xml:lang="ru">Goldstone J.V., Sundaramoorthy M., Zhao Bet al. Genetic and structural analyses of cytochrome P450 hydroxylases in sex hormone biosynthesis: sequential origin and subsequent coevolution. Mol Phylogenet Evol. 2016;94(Pt B):676–87. https://doi.org/10.1016/j.ympev.2015.09.012.</mixed-citation><mixed-citation xml:lang="en">Goldstone J.V., Sundaramoorthy M., Zhao Bet al. Genetic and structural analyses of cytochrome P450 hydroxylases in sex hormone biosynthesis: sequential origin and subsequent coevolution. Mol Phylogenet Evol. 2016;94(Pt B):676–87. https://doi.org/10.1016/j.ympev.2015.09.012.</mixed-citation></citation-alternatives></ref><ref id="cit61"><label>61</label><citation-alternatives><mixed-citation xml:lang="ru">Gaasenbeek M., Powell B.L., Sovio U. et al. Large-scale analysis of the relationship between CYP11A promoter variation, polycystic ovarian syndrome, and serum testosterone. J Clin Endocrinol Metab. 2004;89(5):2408–13. https://doi.org/10.1210/jc.2003-031640.</mixed-citation><mixed-citation xml:lang="en">Gaasenbeek M., Powell B.L., Sovio U. et al. Large-scale analysis of the relationship between CYP11A promoter variation, polycystic ovarian syndrome, and serum testosterone. J Clin Endocrinol Metab. 2004;89(5):2408–13. https://doi.org/10.1210/jc.2003-031640.</mixed-citation></citation-alternatives></ref><ref id="cit62"><label>62</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang C.W., Zhang X.L., Xia Y.J. et al. Association between polymorphisms of the CYP11A1 gene and polycystic ovary syndrome in Chinese women. Mol Biol Rep. 2012;39(8):8379–85. https://doi.org/10.1007/s11033-012-1688-7.</mixed-citation><mixed-citation xml:lang="en">Zhang C.W., Zhang X.L., Xia Y.J. et al. Association between polymorphisms of the CYP11A1 gene and polycystic ovary syndrome in Chinese women. Mol Biol Rep. 2012;39(8):8379–85. https://doi.org/10.1007/s11033-012-1688-7.</mixed-citation></citation-alternatives></ref><ref id="cit63"><label>63</label><citation-alternatives><mixed-citation xml:lang="ru">Louwers Y.V., Stolk L., Uitterlinden A.G., Laven J.S. Cross-ethnic meta-analysis of genetic variants for polycystic ovary syndrome. J Clin Endocrinol Metab. 2013;98(12):E2006–E2012. https://doi.org/10.1210/jc.2013-2495.</mixed-citation><mixed-citation xml:lang="en">Louwers Y.V., Stolk L., Uitterlinden A.G., Laven J.S. Cross-ethnic meta-analysis of genetic variants for polycystic ovary syndrome. J Clin Endocrinol Metab. 2013;98(12):E2006–E2012. https://doi.org/10.1210/jc.2013-2495.</mixed-citation></citation-alternatives></ref><ref id="cit64"><label>64</label><citation-alternatives><mixed-citation xml:lang="ru">Harris H.R., Terry K.L. Polycystic ovary syndrome and risk of endometrial, ovarian, and breast cancer: a systematic review. Fertil Res Pract. 2016;2:14. https://doi.org/10.1186/s40738-016-0029-2.</mixed-citation><mixed-citation xml:lang="en">Harris H.R., Terry K.L. Polycystic ovary syndrome and risk of endometrial, ovarian, and breast cancer: a systematic review. Fertil Res Pract. 2016;2:14. https://doi.org/10.1186/s40738-016-0029-2.</mixed-citation></citation-alternatives></ref><ref id="cit65"><label>65</label><citation-alternatives><mixed-citation xml:lang="ru">Sharma P., Kaur M., Khetarpal P. CYP19 gene rs2414096 variant and differential genetic risk of polycystic ovary syndrome: a systematic review and meta-analysis. Gynecol Endocrinol. 2021;37(2):126–31. https://doi.org/10.1080/09513590.2020.1813274.</mixed-citation><mixed-citation xml:lang="en">Sharma P., Kaur M., Khetarpal P. CYP19 gene rs2414096 variant and differential genetic risk of polycystic ovary syndrome: a systematic review and meta-analysis. Gynecol Endocrinol. 2021;37(2):126–31. https://doi.org/10.1080/09513590.2020.1813274.</mixed-citation></citation-alternatives></ref><ref id="cit66"><label>66</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang Y., Ho K., Keaton J.M. et al. A genome-wide association study of polycystic ovary syndrome identified from electronic health records. Am J Obstet Gynecol. 2020;223(4):559.e1–559.e21. https://doi.org/10.1016/j.ajog.2020.04.004.</mixed-citation><mixed-citation xml:lang="en">Zhang Y., Ho K., Keaton J.M. et al. A genome-wide association study of polycystic ovary syndrome identified from electronic health records. Am J Obstet Gynecol. 2020;223(4):559.e1–559.e21. https://doi.org/10.1016/j.ajog.2020.04.004.</mixed-citation></citation-alternatives></ref><ref id="cit67"><label>67</label><citation-alternatives><mixed-citation xml:lang="ru">Liu Q., Liu H., Bai H. et al. Association of SOD2 A16V and PON2 S311C polymorphisms with polycystic ovary syndrome in Chinese women. J Endocrinol Invest. 2019;42(8):909–21. https://doi.org/10.1007/s40618-018-0999-5.</mixed-citation><mixed-citation xml:lang="en">Liu Q., Liu H., Bai H. et al. Association of SOD2 A16V and PON2 S311C polymorphisms with polycystic ovary syndrome in Chinese women. J Endocrinol Invest. 2019;42(8):909–21. https://doi.org/10.1007/s40618-018-0999-5.</mixed-citation></citation-alternatives></ref><ref id="cit68"><label>68</label><citation-alternatives><mixed-citation xml:lang="ru">Veikkolainen V., Ali N., Doroszko M. et al. Erbb4 regulates the oocyte microenvironment during folliculogenesis. Hum Mol Genet. 2020;29(17):2813–30. https://doi.org/10.1093/hmg/ddaa161.</mixed-citation><mixed-citation xml:lang="en">Veikkolainen V., Ali N., Doroszko M. et al. Erbb4 regulates the oocyte microenvironment during folliculogenesis. Hum Mol Genet. 2020;29(17):2813–30. https://doi.org/10.1093/hmg/ddaa161.</mixed-citation></citation-alternatives></ref><ref id="cit69"><label>69</label><citation-alternatives><mixed-citation xml:lang="ru">Clark K.L., George J.W., Przygrodzka E. et al. Hippo signaling in the ovary: emerging roles in development, fertility, and disease. Endocr Rev. 2022;43(6):1074–96. https://doi.org/10.1210/endrev/bnac013.</mixed-citation><mixed-citation xml:lang="en">Clark K.L., George J.W., Przygrodzka E. et al. Hippo signaling in the ovary: emerging roles in development, fertility, and disease. Endocr Rev. 2022;43(6):1074–96. https://doi.org/10.1210/endrev/bnac013.</mixed-citation></citation-alternatives></ref><ref id="cit70"><label>70</label><citation-alternatives><mixed-citation xml:lang="ru">Wang C., Jeong K., Jiang H. et al. YAP/TAZ regulates insulin signaling via IRS1/2 in endometrial cancer. Am J Cancer Res. 2016;6(5):996–1010. https://pmc.ncbi.nlm.nih.gov/articles/PMC4889715.</mixed-citation><mixed-citation xml:lang="en">Wang C., Jeong K., Jiang H. et al. YAP/TAZ regulates insulin signaling via IRS1/2 in endometrial cancer. Am J Cancer Res. 2016;6(5):996–1010. https://pmc.ncbi.nlm.nih.gov/articles/PMC4889715.</mixed-citation></citation-alternatives></ref><ref id="cit71"><label>71</label><citation-alternatives><mixed-citation xml:lang="ru">Tyrmi J.S., Arffman R.K., Pujol-Gualdo N. et al. Leveraging Northern European population history: novel low-frequency variants for polycystic ovary syndrome. Hum Reprod. 2022;37(2):352–65. https://doi.org/10.1093/humrep/deab250.</mixed-citation><mixed-citation xml:lang="en">Tyrmi J.S., Arffman R.K., Pujol-Gualdo N. et al. Leveraging Northern European population history: novel low-frequency variants for polycystic ovary syndrome. Hum Reprod. 2022;37(2):352–65. https://doi.org/10.1093/humrep/deab250.</mixed-citation></citation-alternatives></ref><ref id="cit72"><label>72</label><citation-alternatives><mixed-citation xml:lang="ru">Al-Awadi A.M., Babi A., Finan R.R. et al. ADIPOQ gene polymorphisms and haplotypes linked to altered susceptibility to polycystic ovary syndrome: a case-control study. Reprod Biomed Online. 2022;45(5):995–1005. https://doi.org/10.1016/j.rbmo.2022.06.009.</mixed-citation><mixed-citation xml:lang="en">Al-Awadi A.M., Babi A., Finan R.R. et al. ADIPOQ gene polymorphisms and haplotypes linked to altered susceptibility to polycystic ovary syndrome: a case-control study. Reprod Biomed Online. 2022;45(5):995–1005. https://doi.org/10.1016/j.rbmo.2022.06.009.</mixed-citation></citation-alternatives></ref><ref id="cit73"><label>73</label><citation-alternatives><mixed-citation xml:lang="ru">Ezzidi I., Mtiraoui N., Mohammed Ali M.E. et al. Adiponectin (ADIPOQ) gene variants and haplotypes in Saudi Arabian women with polycystic ovary syndrome: a case-control study. Gynecol Endocrinol. 2020;36(1):66–71. https://doi.org/10.1080/09513590.2019.1632830.</mixed-citation><mixed-citation xml:lang="en">Ezzidi I., Mtiraoui N., Mohammed Ali M.E. et al. Adiponectin (ADIPOQ) gene variants and haplotypes in Saudi Arabian women with polycystic ovary syndrome: a case-control study. Gynecol Endocrinol. 2020;36(1):66–71. https://doi.org/10.1080/09513590.2019.1632830.</mixed-citation></citation-alternatives></ref><ref id="cit74"><label>74</label><citation-alternatives><mixed-citation xml:lang="ru">Bresciani G., Cruz I.B., de Paz J.A. et al. The MnSOD Ala16Val SNP: relevance to human diseases and interaction with environmental factors. Free Radic Res. 2013;47(10):781–92. https://doi.org/10.3109/10715762.2013.836275.</mixed-citation><mixed-citation xml:lang="en">Bresciani G., Cruz I.B., de Paz J.A. et al. The MnSOD Ala16Val SNP: relevance to human diseases and interaction with environmental factors. Free Radic Res. 2013;47(10):781–92. https://doi.org/10.3109/10715762.2013.836275.</mixed-citation></citation-alternatives></ref><ref id="cit75"><label>75</label><citation-alternatives><mixed-citation xml:lang="ru">Yang Z., Yang X., Xu J. et al. Association between adiponectin receptor 1 gene polymorphism and insulin resistance in Chinese patients with polycystic ovary syndrome. Gynecol Obstet Invest. 2014;77(1):45–9. https://doi.org/10.1016/j.heliyon.2021.e07851.</mixed-citation><mixed-citation xml:lang="en">Yang Z., Yang X., Xu J. et al. Association between adiponectin receptor 1 gene polymorphism and insulin resistance in Chinese patients with polycystic ovary syndrome. Gynecol Obstet Invest. 2014;77(1):45–9. https://doi.org/10.1016/j.heliyon.2021.e07851.</mixed-citation></citation-alternatives></ref><ref id="cit76"><label>76</label><citation-alternatives><mixed-citation xml:lang="ru">Tian Y., Li J., Su S. et al. PCOS-GWAS susceptibility variants in THADA, INSR, TOX3, and DENND1A are associated with metabolic syndrome or insulin resistance in women with polycystic ovary syndrome. Front Endocrinol (Lausanne). 2020;11:274. https://doi.org/10.3389/fendo.2020.00274.</mixed-citation><mixed-citation xml:lang="en">Tian Y., Li J., Su S. et al. PCOS-GWAS susceptibility variants in THADA, INSR, TOX3, and DENND1A are associated with metabolic syndrome or insulin resistance in women with polycystic ovary syndrome. Front Endocrinol (Lausanne). 2020;11:274. https://doi.org/10.3389/fendo.2020.00274.</mixed-citation></citation-alternatives></ref><ref id="cit77"><label>77</label><citation-alternatives><mixed-citation xml:lang="ru">Stephen S.B., Pauline R., Velmurugan S., Subbaraj G.K. Association between fat mass and obesity-associated (FTO) and kisspeptin-1 (KISS1) gene polymorphisms with polycystic ovary syndrome: an updated meta-analysis and power analysis. J Assist Reprod Genet. 2024;41(9):2457–75. https://doi.org/10.1007/s10815-024-03213-7.</mixed-citation><mixed-citation xml:lang="en">Stephen S.B., Pauline R., Velmurugan S., Subbaraj G.K. Association between fat mass and obesity-associated (FTO) and kisspeptin-1 (KISS1) gene polymorphisms with polycystic ovary syndrome: an updated meta-analysis and power analysis. J Assist Reprod Genet. 2024;41(9):2457–75. https://doi.org/10.1007/s10815-024-03213-7.</mixed-citation></citation-alternatives></ref><ref id="cit78"><label>78</label><citation-alternatives><mixed-citation xml:lang="ru">Liu A.L., Xie H.J., Xie H.Y. et al. Association between fat mass and obesity-associated gene rs9939609 A/T polymorphism and polycystic ovary syndrome: a systematic review and meta-analysis. BMC Med Genet. 2017;18(1):89. https://doi.org/10.1186/s12881-017-0452-1.</mixed-citation><mixed-citation xml:lang="en">Liu A.L., Xie H.J., Xie H.Y. et al. Association between fat mass and obesity-associated gene rs9939609 A/T polymorphism and polycystic ovary syndrome: a systematic review and meta-analysis. BMC Med Genet. 2017;18(1):89. https://doi.org/10.1186/s12881-017-0452-1.</mixed-citation></citation-alternatives></ref><ref id="cit79"><label>79</label><citation-alternatives><mixed-citation xml:lang="ru">Janssen J.J.E., Grefte S., Keijer J., de Boer V.C.J. Mito-nuclear communication by mitochondrial metabolites and its regulation by B-vitamins. Front Physiol. 2019;10:78. https://doi.org/10.3389/fphys.2019.00078.</mixed-citation><mixed-citation xml:lang="en">Janssen J.J.E., Grefte S., Keijer J., de Boer V.C.J. Mito-nuclear communication by mitochondrial metabolites and its regulation by B-vitamins. Front Physiol. 2019;10:78. https://doi.org/10.3389/fphys.2019.00078.</mixed-citation></citation-alternatives></ref><ref id="cit80"><label>80</label><citation-alternatives><mixed-citation xml:lang="ru">Divoux A., Erdos E., Whytock K. et al. Transcriptional and DNA methylation signatures of subcutaneous adipose tissue and adipose-derived stem cells in women with polycystic ovary syndrome. Cells. 2022;11(5):848. https://doi.org/10.3390/cells11050848.</mixed-citation><mixed-citation xml:lang="en">Divoux A., Erdos E., Whytock K. et al. Transcriptional and DNA methylation signatures of subcutaneous adipose tissue and adipose-derived stem cells in women with polycystic ovary syndrome. Cells. 2022;11(5):848. https://doi.org/10.3390/cells11050848.</mixed-citation></citation-alternatives></ref><ref id="cit81"><label>81</label><citation-alternatives><mixed-citation xml:lang="ru">Geng X., Zhao J., Huang J. et al. lnc-MAP3K13-7:1 inhibits ovarian granulosa cell proliferation in polycystic ovary syndrome via DNMT1 downregulation-mediated CDKN1A promoter hypomethylation. Mol Ther. 2021;29(3):1279–93. https://doi.org/10.1186/s13048-024-01392-6.</mixed-citation><mixed-citation xml:lang="en">Geng X., Zhao J., Huang J. et al. lnc-MAP3K13-7:1 inhibits ovarian granulosa cell proliferation in polycystic ovary syndrome via DNMT1 downregulation-mediated CDKN1A promoter hypomethylation. Mol Ther. 2021;29(3):1279–93. https://doi.org/10.1186/s13048-024-01392-6.</mixed-citation></citation-alternatives></ref><ref id="cit82"><label>82</label><citation-alternatives><mixed-citation xml:lang="ru">Guo X., Puttabyatappa M., Thompson R.C., Padmanabhan V. Developmental Programming: contribution of epigenetic enzymes to antral follicular defects in the sheep model of polycystic ovary syndrome. Endocrinology. 2019;160(10):2471–84. https://doi.org/10.1210/en.2019-00389.</mixed-citation><mixed-citation xml:lang="en">Guo X., Puttabyatappa M., Thompson R.C., Padmanabhan V. Developmental Programming: contribution of epigenetic enzymes to antral follicular defects in the sheep model of polycystic ovary syndrome. Endocrinology. 2019;160(10):2471–84. https://doi.org/10.1210/en.2019-00389.</mixed-citation></citation-alternatives></ref><ref id="cit83"><label>83</label><citation-alternatives><mixed-citation xml:lang="ru">Dayeh T., Volkov P., Salö S. et al. Genome-wide DNA methylation analysis of human pancreatic islets from type 2 diabetic and non-diabetic donors identifies candidate genes that influence insulin secretion. PLoS Genet. 2014;10(3):e1004160. https://doi.org/10.1371/journal.pgen.1004160.</mixed-citation><mixed-citation xml:lang="en">Dayeh T., Volkov P., Salö S. et al. Genome-wide DNA methylation analysis of human pancreatic islets from type 2 diabetic and non-diabetic donors identifies candidate genes that influence insulin secretion. PLoS Genet. 2014;10(3):e1004160. https://doi.org/10.1371/journal.pgen.1004160.</mixed-citation></citation-alternatives></ref><ref id="cit84"><label>84</label><citation-alternatives><mixed-citation xml:lang="ru">Hosseini E., Shahhoseini M., Afsharian P. et al. Role of epigenetic modifications in aberrant CYP19A1 gene expression in polycystic ovary syndrome. Arch Med Sci. 2019;15(4):887-895. https://doi.org/10.5114/aoms.2019.86060.</mixed-citation><mixed-citation xml:lang="en">Hosseini E., Shahhoseini M., Afsharian P. et al. Role of epigenetic modifications in aberrant CYP19A1 gene expression in polycystic ovary syndrome. Arch Med Sci. 2019;15(4):887-895. https://doi.org/10.5114/aoms.2019.86060.</mixed-citation></citation-alternatives></ref><ref id="cit85"><label>85</label><citation-alternatives><mixed-citation xml:lang="ru">García-Gómez E., Gómez-Viais Y.I., Cruz-Aranda M.M. et al. The effect of metformin and carbohydrate-controlled diet on DNA methylation and gene expression in the endometrium of women with polycystic ovary syndrome. Int J Mol Sci. 2023;24(7):6857. https://doi.org/10.3390/ijms24076857.</mixed-citation><mixed-citation xml:lang="en">García-Gómez E., Gómez-Viais Y.I., Cruz-Aranda M.M. et al. The effect of metformin and carbohydrate-controlled diet on DNA methylation and gene expression in the endometrium of women with polycystic ovary syndrome. Int J Mol Sci. 2023;24(7):6857. https://doi.org/10.3390/ijms24076857.</mixed-citation></citation-alternatives></ref><ref id="cit86"><label>86</label><citation-alternatives><mixed-citation xml:lang="ru">Zhong X., Jin F., Huang C. et al. DNA methylation of AMHR II and INSR genes is associated with the pathogenesis of polycystic ovary syndrome. Technol Health Care. 2021;29(S1):11–25. https://doi.org/10.3233/THC-218002.</mixed-citation><mixed-citation xml:lang="en">Zhong X., Jin F., Huang C. et al. DNA methylation of AMHR II and INSR genes is associated with the pathogenesis of polycystic ovary syndrome. Technol Health Care. 2021;29(S1):11–25. https://doi.org/10.3233/THC-218002.</mixed-citation></citation-alternatives></ref><ref id="cit87"><label>87</label><citation-alternatives><mixed-citation xml:lang="ru">Zhao H., Zhao Y., Ren Y. et al. Epigenetic regulation of an adverse metabolic phenotype in polycystic ovary syndrome: impact of leukocyte methylation of the PPARGC1A promoter. Fertil Steril. 2017;107(2):467–74.e5. https://doi.org/10.1016/j.fertnstert.2016.10.039.</mixed-citation><mixed-citation xml:lang="en">Zhao H., Zhao Y., Ren Y. et al. Epigenetic regulation of an adverse metabolic phenotype in polycystic ovary syndrome: impact of leukocyte methylation of the PPARGC1A promoter. Fertil Steril. 2017;107(2):467–74.e5. https://doi.org/10.1016/j.fertnstert.2016.10.039.</mixed-citation></citation-alternatives></ref><ref id="cit88"><label>88</label><citation-alternatives><mixed-citation xml:lang="ru">Skov V., Glintborg D., Knudsen S. et al. Reduced expression of nuclear-encoded genes involved in mitochondrial oxidative metabolism in skeletal muscle of insulin-resistant women with polycystic ovary syndrome. Diabetes. 2007;56(9):2349–55. https://doi.org/10.2337/db07-0275.</mixed-citation><mixed-citation xml:lang="en">Skov V., Glintborg D., Knudsen S. et al. Reduced expression of nuclear-encoded genes involved in mitochondrial oxidative metabolism in skeletal muscle of insulin-resistant women with polycystic ovary syndrome. Diabetes. 2007;56(9):2349–55. https://doi.org/10.2337/db07-0275.</mixed-citation></citation-alternatives></ref><ref id="cit89"><label>89</label><citation-alternatives><mixed-citation xml:lang="ru">Lambertini L., Saul S.R., Copperman A.B. et al. Intrauterine reprogramming of the polycystic ovary syndrome: evidence from a pilot study of cord blood global methylation analysis. Front Physiol. 2017;8:352. https://doi.org/10.3389/fendo.2017.00352.</mixed-citation><mixed-citation xml:lang="en">Lambertini L., Saul S.R., Copperman A.B. et al. Intrauterine reprogramming of the polycystic ovary syndrome: evidence from a pilot study of cord blood global methylation analysis. Front Physiol. 2017;8:352. https://doi.org/10.3389/fendo.2017.00352.</mixed-citation></citation-alternatives></ref><ref id="cit90"><label>90</label><citation-alternatives><mixed-citation xml:lang="ru">Kokosar M., Benrick A., Perfilyev A. et al. Epigenetic and transcriptional alterations in human adipose tissue of polycystic ovary syndrome. Sci Rep. 2016;6:22883. https://doi.org/10.1038/srep22883.</mixed-citation><mixed-citation xml:lang="en">Kokosar M., Benrick A., Perfilyev A. et al. Epigenetic and transcriptional alterations in human adipose tissue of polycystic ovary syndrome. Sci Rep. 2016;6:22883. https://doi.org/10.1038/srep22883.</mixed-citation></citation-alternatives></ref><ref id="cit91"><label>91</label><citation-alternatives><mixed-citation xml:lang="ru">Sinha N., Roy S., Huang B. et al. Developmental programming: prenatal testosterone-induced epigenetic modulation and its effect on gene expression in sheep ovary. Biol Reprod. 2020;102(5):1045–54. https://doi.org/10.1093/biolre/ioaa007.</mixed-citation><mixed-citation xml:lang="en">Sinha N., Roy S., Huang B. et al. Developmental programming: prenatal testosterone-induced epigenetic modulation and its effect on gene expression in sheep ovary. Biol Reprod. 2020;102(5):1045–54. https://doi.org/10.1093/biolre/ioaa007.</mixed-citation></citation-alternatives></ref><ref id="cit92"><label>92</label><citation-alternatives><mixed-citation xml:lang="ru">Chen J., Zhu Z., Xu S. et al. HDAC1 participates in polycystic ovary syndrome through histone modification by regulating H19/miR-29a-3p/NLRP3-mediated granulosa cell pyroptosis. Mol Cell Endocrinol. 2023;573:111950. https://doi.org/10.1016/j.mce.2023.111950.</mixed-citation><mixed-citation xml:lang="en">Chen J., Zhu Z., Xu S. et al. HDAC1 participates in polycystic ovary syndrome through histone modification by regulating H19/miR-29a-3p/NLRP3-mediated granulosa cell pyroptosis. Mol Cell Endocrinol. 2023;573:111950. https://doi.org/10.1016/j.mce.2023.111950.</mixed-citation></citation-alternatives></ref><ref id="cit93"><label>93</label><citation-alternatives><mixed-citation xml:lang="ru">Wei Y., Wang Z., Wei L. et al. MicroRNA-874-3p promotes testosterone-induced granulosa cell apoptosis by suppressing HDAC1-mediated p53 deacetylation. Exp Ther Med. 2021;21:359. https://doi.org/10.3892/etm.2021.9790.</mixed-citation><mixed-citation xml:lang="en">Wei Y., Wang Z., Wei L. et al. MicroRNA-874-3p promotes testosterone-induced granulosa cell apoptosis by suppressing HDAC1-mediated p53 deacetylation. Exp Ther Med. 2021;21:359. https://doi.org/10.3892/etm.2021.9790.</mixed-citation></citation-alternatives></ref><ref id="cit94"><label>94</label><citation-alternatives><mixed-citation xml:lang="ru">Liu X.M., Yan M.Q., Ji S.Y. et al. Loss of oocyte Rps26 in mice arrests oocyte growth and causes premature ovarian failure. Cell Death Dis. 2018;9(12):1144. https://doi.org/10.1038/s41419-018-1196-3.</mixed-citation><mixed-citation xml:lang="en">Liu X.M., Yan M.Q., Ji S.Y. et al. Loss of oocyte Rps26 in mice arrests oocyte growth and causes premature ovarian failure. Cell Death Dis. 2018;9(12):1144. https://doi.org/10.1038/s41419-018-1196-3.</mixed-citation></citation-alternatives></ref><ref id="cit95"><label>95</label><citation-alternatives><mixed-citation xml:lang="ru">Wang D., Zhu Z., Fu Y. et al. Bromodomain-containing protein 4 activates androgen receptor transcription and promotes ovarian fibrosis in polycystic ovary syndrome. Cell Rep. 2023;42(9):113090. https://doi.org/10.1016/j.celrep.2023.113090.</mixed-citation><mixed-citation xml:lang="en">Wang D., Zhu Z., Fu Y. et al. Bromodomain-containing protein 4 activates androgen receptor transcription and promotes ovarian fibrosis in polycystic ovary syndrome. Cell Rep. 2023;42(9):113090. https://doi.org/10.1016/j.celrep.2023.113090.</mixed-citation></citation-alternatives></ref><ref id="cit96"><label>96</label><citation-alternatives><mixed-citation xml:lang="ru">Roy S., Abudu A., Salinas I. et al. Androgen-mediated perturbation of the hepatic circadian system through epigenetic modulation promotes NAFLD in polycystic ovary syndrome mice. Endocrinology. 2022;163(10):bqac127. https://doi.org/10.1210/endocr/bqac127.</mixed-citation><mixed-citation xml:lang="en">Roy S., Abudu A., Salinas I. et al. Androgen-mediated perturbation of the hepatic circadian system through epigenetic modulation promotes NAFLD in polycystic ovary syndrome mice. Endocrinology. 2022;163(10):bqac127. https://doi.org/10.1210/endocr/bqac127.</mixed-citation></citation-alternatives></ref><ref id="cit97"><label>97</label><citation-alternatives><mixed-citation xml:lang="ru">Mu L., Sun X., Tu M., Zhang D. Non-coding RNAs in polycystic ovary syndrome: a systematic review and meta-analysis. Reprod Biol Endocrinol. 2021;19(1):10. https://doi.org/10.1186/s12958-020-00687-9.</mixed-citation><mixed-citation xml:lang="en">Mu L., Sun X., Tu M., Zhang D. Non-coding RNAs in polycystic ovary syndrome: a systematic review and meta-analysis. Reprod Biol Endocrinol. 2021;19(1):10. https://doi.org/10.1186/s12958-020-00687-9.</mixed-citation></citation-alternatives></ref><ref id="cit98"><label>98</label><citation-alternatives><mixed-citation xml:lang="ru">Vitale S.G., Fulghesu A.M., Mikuš M. et al. The translational role of miRNA in polycystic ovary syndrome: from bench to bedside – a systematic literature review. Biomedicines. 2022;10(8):1816. https://doi.org/10.3390/biomedicines10081816.</mixed-citation><mixed-citation xml:lang="en">Vitale S.G., Fulghesu A.M., Mikuš M. et al. The translational role of miRNA in polycystic ovary syndrome: from bench to bedside – a systematic literature review. Biomedicines. 2022;10(8):1816. https://doi.org/10.3390/biomedicines10081816.</mixed-citation></citation-alternatives></ref><ref id="cit99"><label>99</label><citation-alternatives><mixed-citation xml:lang="ru">Udesen P.B., Sørensen A.E., Svendsen R. et al. Circulating miRNAs in women with polycystic ovary syndrome: a longitudinal cohort study. Cells. 2023;12(7):983. https://doi.org/10.3390/cells12070983.</mixed-citation><mixed-citation xml:lang="en">Udesen P.B., Sørensen A.E., Svendsen R. et al. Circulating miRNAs in women with polycystic ovary syndrome: a longitudinal cohort study. Cells. 2023;12(7):983. https://doi.org/10.3390/cells12070983.</mixed-citation></citation-alternatives></ref><ref id="cit100"><label>100</label><citation-alternatives><mixed-citation xml:lang="ru">Liu D., Wan X., Shan X., Fan R., Zha W. Drugging the “undruggable” microRNAs. Cell Mol Life Sci. 2021;78(5):1861–71. https://doi.org/10.1016/j.patter.2023.100909.</mixed-citation><mixed-citation xml:lang="en">Liu D., Wan X., Shan X., Fan R., Zha W. Drugging the “undruggable” microRNAs. Cell Mol Life Sci. 2021;78(5):1861–71. https://doi.org/10.1016/j.patter.2023.100909.</mixed-citation></citation-alternatives></ref><ref id="cit101"><label>101</label><citation-alternatives><mixed-citation xml:lang="ru">Huang C.C., Yang P.K., Huang Y.S. et al. The role of circulating miRNAs in the mechanism of action and prediction of therapeutic responses of metformin in polycystic ovarian syndrome. Fertil Steril. 2023;119(5):858–68. https://doi.org/10.1016/j.fertnstert.2022.12.045.</mixed-citation><mixed-citation xml:lang="en">Huang C.C., Yang P.K., Huang Y.S. et al. The role of circulating miRNAs in the mechanism of action and prediction of therapeutic responses of metformin in polycystic ovarian syndrome. Fertil Steril. 2023;119(5):858–68. https://doi.org/10.1016/j.fertnstert.2022.12.045.</mixed-citation></citation-alternatives></ref><ref id="cit102"><label>102</label><citation-alternatives><mixed-citation xml:lang="ru">Li Y., Wang H., Zhou D. et al. Up-regulation of long noncoding RNA SRA promotes cell growth, inhibits apoptosis, and induces estradiol and progesterone secretion in ovarian granulosa cells of mice. Med Sci Monit. 2018;24:2384–90. https://doi.org/10.12659/msm.907138.</mixed-citation><mixed-citation xml:lang="en">Li Y., Wang H., Zhou D. et al. Up-regulation of long noncoding RNA SRA promotes cell growth, inhibits apoptosis, and induces estradiol and progesterone secretion in ovarian granulosa cells of mice. Med Sci Monit. 2018;24:2384–90. https://doi.org/10.12659/msm.907138.</mixed-citation></citation-alternatives></ref><ref id="cit103"><label>103</label><citation-alternatives><mixed-citation xml:lang="ru">Shukla P., Melkani G.C. Mitochondrial epigenetic modifications and nuclear–mitochondrial communication: a new dimension toward understanding and attenuating pathogenesis in women with polycystic ovary syndrome. Rev Endocr Metab Disord. 2023;24(2):317–26. https://doi.org/10.1007/s11154-023-09789-2.</mixed-citation><mixed-citation xml:lang="en">Shukla P., Melkani G.C. Mitochondrial epigenetic modifications and nuclear–mitochondrial communication: a new dimension toward understanding and attenuating pathogenesis in women with polycystic ovary syndrome. Rev Endocr Metab Disord. 2023;24(2):317–26. https://doi.org/10.1007/s11154-023-09789-2.</mixed-citation></citation-alternatives></ref><ref id="cit104"><label>104</label><citation-alternatives><mixed-citation xml:lang="ru">Liu R., Bai S., Zheng S. et al. Identification of the metabolomics signature of human follicular fluid from women with polycystic ovary syndrome and insulin resistance. Dis Markers. 2022;2022:6877541. https://doi.org/10.1155/2022/6877541.</mixed-citation><mixed-citation xml:lang="en">Liu R., Bai S., Zheng S. et al. Identification of the metabolomics signature of human follicular fluid from women with polycystic ovary syndrome and insulin resistance. Dis Markers. 2022;2022:6877541. https://doi.org/10.1155/2022/6877541.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
